These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 20592045)

  • 1. Getting the details right: gene signatures for cancer therapy.
    Master SR
    Clin Chem; 2010 Sep; 56(9):1378-80. PubMed ID: 20592045
    [No Abstract]   [Full Text] [Related]  

  • 2. Preface on application of omics technologies in cancer biology and therapy.
    Georgakilas AG
    Cancer Lett; 2016 Nov; 382(1):A1. PubMed ID: 27765153
    [No Abstract]   [Full Text] [Related]  

  • 3. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
    Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
    Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A gentle introduction to understanding preclinical data for cancer pharmaco-omic modeling.
    Piyawajanusorn C; Nguyen LC; Ghislat G; Ballester PJ
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34368843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genome-Scale Signatures of Gene Interaction from Compound Screens Predict Clinical Efficacy of Targeted Cancer Therapies.
    Jiang P; Lee W; Li X; Johnson C; Liu JS; Brown M; Aster JC; Liu XS
    Cell Syst; 2018 Mar; 6(3):343-354.e5. PubMed ID: 29428415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer genomics and proteomics. Methods and Protocols. Preface.
    Fisher PB
    Methods Mol Biol; 2007; 383():v-vii. PubMed ID: 18429356
    [No Abstract]   [Full Text] [Related]  

  • 7. GESgnExt: Gene Expression Signature Extraction and Meta-Analysis on Gene Expression Omnibus.
    Yan S; Wong KC
    IEEE J Biomed Health Inform; 2020 Jan; 24(1):311-318. PubMed ID: 30714937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do predictive signatures really predict response to cancer chemotherapy?
    Borst P; Wessels L
    Cell Cycle; 2010 Dec; 9(24):4836-40. PubMed ID: 21150277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of expression-based biomarkers of Dasatinib response in hematologic malignancies.
    Akre MK; Mitra A; Wang W; Myers CL; Van Ness B
    Blood Cancer J; 2017 Dec; 7(12):652. PubMed ID: 29242603
    [No Abstract]   [Full Text] [Related]  

  • 10. Proteomic profiling predicts drug response to novel targeted anticancer therapeutics.
    Lin F; Li Z; Hua Y; Lim YP
    Expert Rev Proteomics; 2016; 13(4):411-20. PubMed ID: 26954459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Individualized molecular medicine: linking functional proteomics to select therapeutics targeting the PI3K pathway for specific patients.
    Murph MM; Smith DL; Hennessy B; Lu Y; Joy C; Coombes KR; Mills GB
    Adv Exp Med Biol; 2008; 622():183-95. PubMed ID: 18546628
    [No Abstract]   [Full Text] [Related]  

  • 12. Mass spectrometry-based proteomics: from cancer biology to protein biomarkers, drug targets, and clinical applications.
    Jimenez CR; Verheul HM
    Am Soc Clin Oncol Educ Book; 2014; ():e504-10. PubMed ID: 24857147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the Molecular Profiling of Tumor Tissue.
    Resnick MB; Perez K
    R I Med J (2013); 2015 Oct; 98(10):15. PubMed ID: 26422539
    [No Abstract]   [Full Text] [Related]  

  • 14. A community effort to assess and improve drug sensitivity prediction algorithms.
    Costello JC; Heiser LM; Georgii E; Gönen M; Menden MP; Wang NJ; Bansal M; Ammad-ud-din M; Hintsanen P; Khan SA; Mpindi JP; Kallioniemi O; Honkela A; Aittokallio T; Wennerberg K; ; Collins JJ; Gallahan D; Singer D; Saez-Rodriguez J; Kaski S; Gray JW; Stolovitzky G
    Nat Biotechnol; 2014 Dec; 32(12):1202-12. PubMed ID: 24880487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profiling of treatment resistance: hype or hope for therapeutic target identification.
    Helleman J; Jansen MP; Berns EM
    Int J Gynecol Cancer; 2006; 16 Suppl 2():538-42. PubMed ID: 17010068
    [No Abstract]   [Full Text] [Related]  

  • 16. What information should be required to support clinical "omics" publications?
    Baggerly KA; Coombes KR
    Clin Chem; 2011 May; 57(5):688-90. PubMed ID: 21364027
    [No Abstract]   [Full Text] [Related]  

  • 17. [Proteome analysis--basis for individualized pancreatic carcinoma therapy?].
    Löhr JM; Faissner R; Findeisen P; Neumaier M
    Internist (Berl); 2006 Jun; 47 Suppl 1():S40-8. PubMed ID: 16773365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paul Workman: Drugging the Cancer Genome.
    Trends Cancer; 2016 Oct; 2(10):544-548. PubMed ID: 27904887
    [No Abstract]   [Full Text] [Related]  

  • 19. Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.
    Dienstmann R; Jang IS; Bot B; Friend S; Guinney J
    Cancer Discov; 2015 Feb; 5(2):118-23. PubMed ID: 25656898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DNA microarrays and data analysis: an overview.
    Eschrich S; Yeatman TJ
    Surgery; 2004 Sep; 136(3):500-3. PubMed ID: 15349092
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.